Neurocrine Biosciences | NBIX - Current Assets


Neurocrine Biosciences reported $2.16B in Current Assets for its fiscal quarter ending in September of 2025.





Current Assets Change Date
AbbVie USD 28.54B 722M Sep/2025
Acadia Pharmaceuticals USD 1.08B 115.87M Sep/2025
Agios Pharmaceuticals USD 1.03B 13.64M Sep/2025
ALKERMES USD 1.74B 106.38M Sep/2025
Alnylam Pharmaceuticals USD 3.95B 309.11M Sep/2025
Amgen USD 27.88B 1.15B Sep/2025
Biogen USD 8.94B 968.9M Sep/2025
BioMarin Pharmaceutical USD 3.85B 49.21M Sep/2025
Cytokinetics USD 977.35M 90.81M Sep/2025
Dynavax Technologies USD 814.33M 28.62M Sep/2025
Exelixis USD 1.4B 221.5M Sep/2025
Gilead Sciences USD 18.84B 4.12B Sep/2025
Halozyme Therapeutics USD 1.33B 206.08M Sep/2025
Incyte USD 4.28B 634.19M Sep/2025
Ionis Pharmaceuticals USD 2.52B 58.16M Sep/2025
Neurocrine Biosciences USD 2.16B 409.5M Sep/2025
Pfizer USD 46.92B 3.22B Sep/2025
Prothena USD 339.97M 45.51M Sep/2025
Regeneron Pharmaceuticals USD 17.98B 1.12B Sep/2025
Repligen USD 1.1B 39.62M Sep/2025
Sarepta Therapeutics USD 2.72B 65.32M Sep/2025
Teva Pharmaceutical Industries USD 13.95B 1.21B Dec/2025
Ultragenyx Pharmaceutical USD 643.21M 76.58M Sep/2025
Vertex Pharmaceuticals USD 10.57B 141.7M Sep/2025